Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Switch to lopinavir/ritonavir + lamivudine dual therapy in virologically suppressed HIV-1 patients
2010-024652-28Phase 3Completed
- Sponsor
- Fundació Clínic per a la Recerca Biomèdica
- Start
- Sep 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of lopinavir, ritonavir, lamivudine and emtricitabine in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Fundació Clínic per a la Recerca Biomèdica. Primary endpoint: Proportion of patients free from therapeutic failure at 48 weeks. Started Sep 2011; status: completed.
02
Drugs
lopinavirritonavirlamivudineemtricitabine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on 2010-024652-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-024652-28.